First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease.
about
Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer's Disease Immunotherapy.Lessons from Anti-Amyloid-β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target.Efficacy and safety of anti-amyloid-β immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis.Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing.Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease.
P2860
First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease.
description
2016 nî lūn-bûn
@nan
2016 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մարտին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
First-In-Human safety and long ...... moderate Alzheimer's disease.
@ast
First-In-Human safety and long ...... moderate Alzheimer's disease.
@en
type
label
First-In-Human safety and long ...... moderate Alzheimer's disease.
@ast
First-In-Human safety and long ...... moderate Alzheimer's disease.
@en
prefLabel
First-In-Human safety and long ...... moderate Alzheimer's disease.
@ast
First-In-Human safety and long ...... moderate Alzheimer's disease.
@en
P2093
P2860
P1476
First-In-Human safety and long ...... moderate Alzheimer's disease.
@en
P2093
David Jianjun Li
H Robert Brashear
James W Kupiec
Marielle Delnomdedieu
Nazem Atassi
Sridhar Duvvuri
P2860
P2888
P356
10.1186/S13195-016-0177-Y
P407
P577
2016-03-01T00:00:00Z
P6179
1001996768